The study demonstrated that the combination of two oral direct acting anti hepatitis C virus (HCV) compounds (the protease inhibitor BI 201335 and the polymerase inhibitor BI 207127, with and without ribavirin (RBV), could provide virological response rates at week 12 in treatment-naïve patients infected with the most difficult to treat genotype-1.
BI 201335 is an investigational oral HCV NS3/4A protease inhibitor, which has completed clinical trials through Phase IIb (SILEN-C studies)
All five treatment arms of the interferon-free oral combination therapy of BI 201335/BI 207127/RBV showed high virologic response rates through week 12, defined by measuring the level of HCV RNA in patient blood.